Benign Conditions

Benign Prostatic Hyperplasia

Bladder Cancer

Female Urology

Genitourinary Cancers

Genomic Testing

Hormone Therapy

Kidney Cancer

Challenging Anatomy

Innovative Techniques

Laser Lithotripsy

PCNL Tech & Devices

Ureteroscopy Tech & Devices

Kidney Stones

Men's Health

Next-Generation Imaging

Voiding Dysfunction

OAB and Incontinence

Pediatrics

Controveries in Urologic Cancer

Drug Therapy

Prostate Cancer

Sexual Dysfunction

UTUC

Cosmetic Surgery

Urologic Surgery

Business

Practice Management

Malpractice Consult

Health Law & Policy

Media

Case-Based Peer Perspectives

Investigator Perspectives 

Medical World News

Podcasts

Urology Medical Perspectives

UTv Videos

Peer Exchange

Special Report

Virtual Tumor Board

Insights

Medcast

Peers & Perspectives

Conferences

Conference Listing

Conference Previews 

Conference Recaps

Publications

Urology Times Journal

Editorial Advisory Board

Urologists in Cancer Care

Supplements and Featured Publications

Clinical Forums Recaps

CME/CE

Resources

Begin Your Journey: Tackling Burnout

Live Events

Interactive Tools

Job Board

Partners

Treatment Landscape Evolutions

Subscribe

Benjamin P. Saylor is associate editor of Urology Times, an Advanstar Communications publication.

Articles

According to the company, the MHRA approval represents the first marketing approval outside the US for NAI. 

UK’s MHRA approves nogapendekin alfa inbakicept plus BCG in NMIBC

Eligible patients will receive UGN-103 75 mg intravesically once per week for 6 weeks. 

Enrollment complete for phase 3 UTOPIA trial in LG-IR-NMIBC

The data, collected as part of the phase 1/2 Duravelo-1 trial, showed an objective response rate of 65%.

Zelenectide pevedotin plus pembrolizumab shows promising anti-tumor activity in mUC

For the trial, a biomarker will be utilized to aid in patient selection for the treatment.

FDA and EMA authorize phase 3 trial of masitinib for mCRPC

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do not sell my Personnal Information

Urology Times – News & Insights for Urologists & Health Professionals

Facebook

LinkedIn

Spotlight

Peers and Perspectives

Clinical

1rem

Christopher E. Kelly, MD, discusses how emerging pharmaceutical interventions, minimally invasive surgical techniques, and personalized treatment strategies revolutionize management approaches for benign prostatic hyperplasia. He focuses on improving patient outcomes, reducing adverse effects, and addressing the complex symptomatology of this common age-related urological condition.

Advancing Therapies in Benign Prostatic Hyperplasia

Karim Chamie, MD, MSHS, discusses how innovative non–muscle invasive bladder cancer (NMIBC) delivery systems such as TAR-200 offer targeted, less toxic treatment options, showing promise for high-risk patients with improved efficacy and patient tolerance through localized drug administration.

Exploring Novel Delivery Systems to Advance NMIBC Treatment

Mark D. Tyson, II, M.D., M.P.H., explores the current NMIBC landscape, covering risk stratification approaches, established treatments like BCG immunotherapy and TURBT, emerging investigational agents spanning multiple mechanisms of action, and remaining challenges including BCG supply shortages and biomarker development, while highlighting future directions in personalized medicine and novel delivery systems.

Non-muscle Invasive Bladder Cancer Treatment Landscape Evolutions 

Katie S. Murray, DO, discusses how advancements in targeted gene therapies and immunotherapeutic options are transforming the management of BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), offering urologists more effective, accessible treatment alternatives and reducing patient burden.

Managing BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer (NMIBC): Clinical and Operational Perspectives

Dean Elterman, MD, explores the latest advancements in minimally invasive treatment options for benign prostatic hyperplasia (BPH), detailing emerging techniques and their impact on patient care

Advances in Minimally Invasive Treatment Options for Benign Prostatic Hyperplasia

Expert insight from David M. Albala, MD, on the evolving landscape of imaging modalities in prostate cancer and how it has impacted treatment pathways.

Use of Targeted Imaging Modalities in Prostate Cancer: Key Challenges and Considerations  

Amir H. Lebastchi, MD, investigates advancements in precision-based approaches to prostate cancer diagnosis and therapy, with a focus on the role of MRI and ultrasound fusion technologies.

Updates in Precision-Based Approaches to Prostate Cancer Diagnosis and Treatment

Boris Gershman, MD discusses recent advancements in prostate cancer imaging, touching on the clinical application of multiparametric MRI (mpMRI), effective strategies for communication between urologists and radiologists, and how machine learning may shape the future of prostate cancer imaging.

Strategies for Communication and Collaboration in Prostate Cancer Care

Gerald Andriole, MD discusses pre-biopsy biomarker testing as a risk assessment tool in patients suspected of having prostate cancer, highlighting key advantages and reviewing available options and clinical data, and shares his clinical experience regarding implementation.

Biomarker Testing for Risk Assessment of Patients Suspected of Having Prostate Cancer

Mark Emberton, BSc, MBBS, FRSC (Urol), MD, FMedSci, provides a historical perspective on treatment options for clinically localized prostate cancer, reviews emerging focal therapy options including HIFU, and discusses how focal therapy has impacted the field.

Focal Therapy Options for Localized Prostate Cancer

John J. Kowalczyk, DO, FACOS, shares his experience and perspectives on urology practice management and implementing software tools to improve practice workflows.

Addressing Challenges in Urology Practice Management

Stephen J. Freedland, MD, provides an overview of the diagnosis and staging of high-risk, clinically localized prostate cancer and explains how genomic testing helps inform risk stratification and treatment-decision making in his clinical practice.

Updates on Use of Genomic Testing in Patients with High-Risk, Clinically Localized Prostate Cancer

Expert perspectives on the use of saw palmetto extracts to manage patients with benign prostatic hyperplasia and lower urinary tract symptoms.

Lipidosterolic Extract of Serenoa repens (Saw Palmetto) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

Robert Dreicer, MD, provides an overview of advances in the treatment of metastatic castration-resistant prostate cancer (mCRPC) and available and emerging second-line treatment options for mCRPC.

Second-Line Treatment Options in Advanced Prostate Cancer

Kyle Wood, MD, reviews currently available treatment options for enteric hyperoxaluria and the importance of disease education.

Enteric Hyperoxaluria: Understanding the Disease

Brad Schwartz, DO, FACS, comments on newer urologic imaging techniques that can reduce exposure to radiation.

The Importance of Image Quality in the Urological Workflow

Dr. Neal Shore reviews treatment options in metastatic castration-resistant prostate cancer available in 2020.

Treatment Options in Metastatic Castration-Resistant Prostate Cancer: A Year In Review